Accelrys buys web-based drug discovery solution from Scynexis
Accelrys, a scientific enterprise R&D software and services company, has purchased the web-based drug discovery information management technology, Hit Explorer Operating System (HEOS) from Scynexis.
HEOS is a Software-as-a-Service (SaaS) workspace that accelerates and streamlines collaborative drug discovery by providing secure, real-time access to chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information in the Cloud.
The cloud based drug discovery information management technology enables efficient and streamlined drug discovery collaborations, particularly for organizations leveraging academic departments, research institutes and contract research organizations (CROs) in externalized R&D projects.
Accelrys president and chief executive officer Max Carnecchia said HEOS supports an important new operating model for collaborating organizations that require secure, flexible information management and collaboration with global reach.
"As many of our customers move to multi-site, multi-collaborator projects to accelerate innovation and reduce costs, we look forward to broadening the applicability and reach of HEOS as a secure, easy-to-use, Cloud-based information management workspace for the wider scientific community," Carnecchia added.